The first clinical-grade, GMP-compliant bioprinter. Built on the NGB-R® architecture for a seamless continuum from research to clinical translation. Ideal for regenerative medicine.
The NGB-C® shares its architecture with the NGB-R®. Every strategy you develop in research carries over, with no rework, into a clinical-grade environment. The same heads, the same software, now under GMP-compatible conditions.
It is the bridge that takes a discovery from the bench to a manufacturable, regulated therapy.
Start in research with NGB-R® →
NGB-R®, where the workflow begins.
Biosafety and compliance are built into the platform, from the cabinet to the audit trail.
Sterilizable laminar flow, vertical airflow.
Removable, autoclavable accessories.
Every step recorded across the build.
Sterility-preserving QC, in process.
Manufacture advanced therapy medicinal products under conditions designed for the clinic.
The first bioprinted product reaching clinical translation, manufactured on the NGB-C®.
A dermo-epidermal skin substitute, manufactured under GMP-compatible conditions on the NGB-C®.
Autologous skin substitute per build
BIOPSKIN trial in progress, AP-HM Marseille
Permanent wound coverage where autologous, full-thickness tissue makes the difference.
The Poieskin® program is conducted with clinical investigators at AP-HM, Marseille. Names & titles to be confirmed.
The NGB-C® opens clinical and translational programs across high-value indications.
Therapeutic tissues for permanent repair, from skin to beyond.
Discuss your regulatory roadmap with our scientists, from your first prototype to GMP-compatible production.